In mice bearing tumors derived from mouse 4T1 breast cancer cells, the prodrug 42 (1 mg/kg, iv, 6× every other day) decreased Gpx4 and increased Egr1 protein levels and inhibited tumor growth. Here, GPX4 is linked to breast carcinoma.